Panmure Gordon Reaffirms “Hold” Rating for Hikma Pharmaceuticals Plc (HIK)
Hikma Pharmaceuticals Plc (LON:HIK)‘s stock had its “hold” rating reiterated by Panmure Gordon in a research note issued on Tuesday. They currently have a GBX 1,580 ($26.41) price target on the stock. Panmure Gordon’s price target suggests a potential downside of 11.88% from the stock’s previous close.
Shares of Hikma Pharmaceuticals Plc (LON:HIK) opened at 1806.00 on Tuesday. Hikma Pharmaceuticals Plc has a 52 week low of GBX 1004.00 and a 52 week high of GBX 1835.00. The stock’s 50-day moving average is GBX 1748. and its 200-day moving average is GBX 1595.. The company’s market cap is £3.571 billion.
HIK has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 14th. They now have a GBX 1,900 ($31.76) price target on the stock. Separately, analysts at Barclays reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Thursday, August 14th. Finally, analysts at Barclays reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Friday, August 1st. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of GBX 1,795.71 ($30.02).
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.